Project Grant HT94252410322
Award Date
7/1/24
Completion Date
6/30/28
Dollars Obligated
$665K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Minneapolis, MN 55455, USA
Similar Awards
The University of Minnesota has been awarded a $574,666 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "Trapping Inhibitory Signals in Synergy with Cytokine Signaling to Maximize NK Cell Immunotherapy in Ovarian Cancer." This grant, effective July 1, 2024 through June 30, 2028, will support the university's innovative research aimed at developing new treatments and...
The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $787,793 Project Grant to the Regents of the University of Minnesota to conduct research on "LEVERAGING TARGETED BIOLOGICAL COMPLEXES TO MAXIMIZE NATURAL KILLER CELL IMMUNOTHERAPY IN LUNG CANCER". The three-year award, running from July 1, 2024 to June 30, 2027, will support the university's efforts to develop innovative immunotherapy approaches for treating lung cancer, with a...
The Regents of the University of Minnesota received a $515,187 Project Grant award from the Defense Health Agency to conduct research titled "Leveraging Reactivation of Tissue-Resident Memory T Cells in the Tumor Microenvironment for Oncolytic Virotherapy." The grant is part of the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform military and public health care through innovative medical...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program provides $614,150.00 to the Regents of the University of Minnesota to enhance the long-term persistence of CAR-NK cells for the treatment of solid tumors. The award commenced on July 1, 2025 and is scheduled for completion on June 30, 2027. As a prominent land-grant research institution, the University of Minnesota has a sophisticated and diverse...
This $1,155,000.00 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program will fund the University of Minnesota to evaluate prostate cancer patient natural killer cell function across racial backgrounds and address functional disparities with trispecific killer engagers. The award runs from June 1, 2025 through May 31, 2029 and supports advanced biomedical research focused on transforming healthcare for military service...
The University of Minnesota, through its Office of Sponsored Projects Administration, was awarded a $1,521,386 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to engage the immune system to kill sarcoma through a comparative oncology approach. The 3-year grant, which began on July 15, 2023 and will be completed by July 14, 2026, supports basic, applied, and advanced biomedical research to transform healthcare for service...
The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $1,243,750 Project Grant to the Regents of the University of Minnesota, doing business as the Office of Sponsored Projects Administration, to develop allogeneic, multiplex base-edited, dual-targeted gamma delta CAR-T cell therapies for the treatment of metastatic castration-resistant prostate cancer. This 3-year award, with a project period from Sep 30, 2024 to Sep 29, 2027, will...
This $1,539,818.00 Department of the Army Medical Command federal Project Grant award under the Military Medical Research and Development program (CFDA 12.420) will fund research led by the Regents of the University of Minnesota to develop multiplex edited, dual CAR gamma delta T cells targeting pediatric solid tumors. The three-year project, with a performance period from November 15, 2024 to November 14, 2027, seeks to advance innovative cell-based immunotherapies for the treatment of...
This Project Grant award, worth $617,868.00, was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the Regents of the University of Minnesota. The funding supports an evaluation of a novel TRIKE-PACC molecule to amplify natural killer cell function in mesothelioma, a type of cancer. The research aims to improve health outcomes for military service members, veterans, and the broader public. The award commenced on July 15, 2024 and...
This federal Project Grant award from the Department of the Army Medical Command (CFDA 12.420 - Military Medical Research and Development) provides $1,348,041.00 to the Regents of the University of Minnesota to develop a RET-specific proteomic assay from circulating tumor cells in lethal prostate cancer. The award began on Mar 1, 2024 and is scheduled for completion by Feb 28, 2027. This research aims to transform health care for military service members and the general public through innovative...